Strengthening our R&D capabilities, a cornerstone of our pharmaceutical business
Since 1987, we have been expanding steadily. We opened our Central Pharmaceutical Research Institute in Osaka in 1993, and established a clinical development base outside Japan in 2000 with the addition of our development function to Akros Pharma Inc., our US subsidiary. We focus mainly on the fields of metabolic diseases, autoimmune/inflammatory diseases and viral infection.
We are accelerating development in order to provide patients with our drugs as soon as possible. We are enhancing our research and development pipeline, exploring opportunities for strategic in- or out-licensing and strengthening collaboration with our license partners.